Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 41, 2012, Pages 16666-16671

  Gordon, Leslie B ^a,b,c   Kleinman, Monica E ^a,b   Miller, David T ^a,b   Neuberg, Donna S ^d,e   Giobbie Hurder, Anita ^d   Gerhard Herman, Marie ^f   Smoot, Leslie B ^a   Gordon, Catherine M ^b,c   Cleveland, Robert ^a   Snyder, Brian D ^a   Fligor, Brian ^a   Bishop, W Robert ^g   Statkevich, Paul ^g   Regen, Amy ^a   Sonis, Andrew ^a   Riley, Susan ^a   Ploski, Christine ^a   Correia, Annette ^a   Quinn, Nicolle ^b   Ullrich, Nicole J ^b   Nazarian, Ara ^a   Liang, Marilyn G ^a,b   Huh, Susanna Y ^a,b   Schwartzman, Armin ^d,e   Kieran, Mark ^b,d   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c BROWN UNIVERSITY   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cardiovascular disease; Laminopathy; SCH66336; Translational medicine

Indexed keywords

LAMIN A; LONAFARNIB; PROGERIN PROTEIN; UNCLASSIFIED DRUG;

ANOREXIA; AREA UNDER THE CURVE; ARTERIAL STIFFNESS; ARTICLE; BLOOD VESSEL WALL; BONE DENSITY; BONE STRUCTURE; CAROTID ARTERY; CHILD; CLINICAL ARTICLE; DIARRHEA; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG ELIMINATION; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FATIGUE; FEMALE; HEARING IMPAIRMENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PRIORITY JOURNAL; PROGERIA; PULSE WAVE; RIGIDITY; SCHOOL CHILD; SIDE EFFECT; SKELETAL RIGIDITY; STEADY STATE; TREATMENT DURATION; VOMITING; WEIGHT GAIN;

ADOLESCENT; CAROTID ARTERIES; CHILD; CHILD, PRESCHOOL; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FATIGUE; FEMALE; HUMANS; MALE; PIPERIDINES; PROGERIA; PULSE WAVE ANALYSIS; PYRIDINES; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN;

EID: 84867380060     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1202529109     Document Type: Article

References (41)

1. Kieran MW, Gordon L, Kleinman M (2007) New approaches to progeria. Pediatrics 120:834-841. (Pubitemid 47549572)
2. De Sandre-Giovannoli A, et al. (2003) Lamin a truncation in Hutchinson-Gilford progeria. Science 300:2055. (Pubitemid 36760124)
3. Eriksson M, et al. (2003) Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 423:293-298. (Pubitemid 40852699)
4. Broers JL, Ramaekers FC, Bonne G, Yaou RB, Hutchison CJ (2006) Nuclear lamins: Laminopathies and their role in premature ageing. Physiol Rev 86:967-1008. (Pubitemid 44042881)
5. Goldman RD, et al. (2004) Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 101:8963-8968. (Pubitemid 38781594)
6. Merideth MA, et al. (2008) Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med 358:592-604. (Pubitemid 351214286)
7. Hennekam RC (2006) Hutchinson-Gilford progeria syndrome: Review of the phenotype. Am J Med Genet A 140:2603- 2624.
8. Basso AD, Kirschmeier P, Bishop WR (2006) Lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res 47:15-31.
9. Rusiñol AE, Sinensky MS (2006) Farnesylated lamins, progeroid syndromes and farnesyl transferase inhibitors. J Cell Sci 119:3265-3272. (Pubitemid 44405212)
10. Capell BC, et al. (2008) A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. Proc Natl Acad Sci USA 105:15902-15907.
11. Yang SH, et al. (2006) A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J Clin Invest 116:2115-2121. (Pubitemid 44162320)
12. Kieran MW, et al. (2007) Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: A Pediatric Brain Tumor Consortium Study. J Clin Oncol 25:3137-3143. (Pubitemid 47218063)
13. Gordon LB, et al. (2007) Disease progression in Hutchinson-Gilford progeria syndrome: Impact on growth and development. Pediatrics 120:824-833. (Pubitemid 47549571)
14. The Progeria Research Foundation International Registry. Available at http://www.progeriaresearch.org/patient-registry.html.
15. Gordon CM, et al. (2011) Hutchinson-Gilford progeria is a skeletal dysplasia. J Bone Miner Res 26:1670-1679.
16. Gerhard-Herman M, et al. (2012) Mechanisms of premature vascular aging in children with Hutchinson-Gilford progeria syndrome. Hypertension 59:92-97.
17. Wren TA, Liu X, Pitukcheewanont P, Gilsanz V (2005) Bone acquisition in healthy children and adolescents: Comparisons of dual-energy x-ray absorptiometry and computed tomography measures. J Clin Endocrinol Metab 90:1925-1928. (Pubitemid 40586222)
18. Schofield WN (1985) Predicting basal metabolic rate, new standards and review of previous work. Hum Nutr Clin Nutr 39(Suppl 1):5- 41.
19. Reusz GS, et al. (2010) Reference values of pulse wave velocity in healthy children and teenagers. Hypertension 56:217-224.
20. Kis E, et al. (2008) Pulse wave velocity in end-stage renal disease: Influence of age and body dimensions. Pediatr Res 63:95-98.
21. Feldman EJ, et al. (2008) On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia 22:1707-1711.
22. Domingo DL, et al. (2009) Hutchinson-Gilford progeria syndrome: Oral and craniofacial phenotypes. Oral Dis 15:187-195.
23. O'Rourke MF, Staessen JA, Vlachopoulos C, Duprez D, Plante GE (2002) Clinical applications of arterial stiffness; definitions and reference values. Am J Hypertens 15:426-444. (Pubitemid 34478483)
24. Redheuil A, et al. (2010) Reduced ascending aortic strain and distensibility: Earliest manifestations of vascular aging in humans. Hypertension 55:319-326.
25. Cruickshank K, et al. (2002) Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: An integrated index of vascular function? Circulation 106:2085-2090. (Pubitemid 35192814)
26. Varga R, et al. (2006) Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 103:3250-3255. (Pubitemid 43346456)
27. Olive M, et al. (2010) Cardiovascular pathology in Hutchinson-Gilford progeria: Correlation with the vascular pathology of aging. Arterioscler Thromb Vasc Biol 30:2301-2309.
28. Lind L, Andersson J, Rönn M, Gustavsson T (2007) The echogenecity of the intimamedia complex in the common carotid artery is closely related to the echogenecity in plaques. Atherosclerosis 195:411-414. (Pubitemid 350087964)
29. Stehbens WE, Delahunt B, Shozawa T, Gilbert-Barness E (2001) Smooth muscle cell depletion and collagen types in progeric arteries. Cardiovasc Pathol 10:133-136. (Pubitemid 32685490)
30. Binkley TL, Berry R, Specker BL (2008) Methods for measurement of pediatric bone. Rev Endocr Metab Disord 9:95-106.
31. Bertrand AT, Chikhaoui K, Yaou RB, Bonne G (2011) Clinical and genetic heterogeneity in laminopathies. Biochem Soc Trans 39:1687-1692.
32. James GL, Goldstein JL, Brown MS (1995) Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem 270:6221-6226.
33. McClintock D, Gordon LB, Djabali K (2006) Hutchinson-Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-Lamin A G608G antibody. Proc Natl Acad Sci USA 103:2154-2159. (Pubitemid 43271639)
34. Scaffidi P, Misteli T (2006) Lamin A-dependent nuclear defects in human aging. Science 312:1059-1063.
35. McClintock D, et al. (2007) The mutant form of lamin A that causes Hutchinson-Gilford progeria is a biomarker of cellular aging in human skin. PLoS ONE 2: e1269.
36. Cao K, et al. (2011) Progerin and telomere dysfunction collaborate to trigger cellular senescence in normal human fibroblasts. J Clin Invest 121:2833- 2844.
37. Scaffidi P, Gordon L, Misteli T (2005) The cell nucleus and aging: Tantalizing clues and hopeful promises. PLoS Biol 3:e395.
38. Fong LG, et al. (2006) A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 311:1621-1623.
39. Gordon CM, et al. (2002) Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: A randomized trial. J Clin Endocrinol Metab 87:4935-4941. (Pubitemid 35316328)
40. Kenna MA, et al. (2010) Audiologic phenotype and progression in GJB2 (Connexin 26) hearing loss. Arch Otolaryngol Head Neck Surg 136:81-87.
41. Kuczmarski RJ, et al. (2002) 2000 CDC Growth Charts for the United States: Methods and Development (National Center for Health Statistics. Vital and Health Statistics, Washington, DC), Series 11, No. 246. Available at http://www.cdc.gov/growthcharts/2000growthchart-us.pdf.